AL

Alex Luce

Partner at Creative Ventures

San Francisco Bay Area

Overview 

Alex Luce is a Partner at Creative Ventures in the San Francisco Bay Area, with a background in materials science and venture capital. He has successfully invested in companies like Relectrify and OncoPrecision, focusing on sectors such as CleanTech and BioTech. With a PhD from the University of California, Berkeley, and a track record of investments in diverse founders, Alex has demonstrated expertise in materials science and strategic leadership, making impactful contributions to the growth of startups in sectors like EnergyTech and ClimateTech.

Work Experience 

  • General Partner

    2017 - Current

    We invest in technologies that directly attack the most pressing global macroeconomic trends, including climate change, demographic changes straining our healthcare system, and secular labor shortages. Our focus includes: climate and the energy transition, advanced manufacturing, construction, synthetic biology, computation, diagnostics and imaging.

  • Investor

    2022

  • Board Observer

    2022

  • Investor

    2021

AM Batteries manufactures Li-ion batteries using solvent-free electrode manufacturing technology.

Raised $62,485,998.00 from Mass. Manufacturing Innovation Initiative.

  • Board Observer

    2021

VenoStent is a tissue engineering medical device company developing bioabsorbable polymer wraps for better outcomes in vascular surgery.

Raised $29,818,706.00 from Good Growth Capital, Norwest Venture Partners, IAG Capital Partners, Creative Ventures, SNR.vc, TMC Venture Fund, IAG Capital Partners, Alumni Ventures and Baylor Angel Network.

  • Investor

    2021

FORT Robotics is a safety and security platform designed to secure autonomous machines from cybersecurity attacks.

Raised $38,000,000.00 from Tiger Global Management, Prologis Ventures, FundersClub, Lemnos VC, Creative Ventures, Compound and GRIDS Capital.

  • Board Observer

    2020

  • Board Member

    2020

IMVARIA brings artificial intelligence to imaging and lab data, re-imagining clinical assessments in serious diseases.

  • Board Member

    2020

Articles About Alex

Relevant Websites